1. Academic Validation
  2. Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration

Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration

  • J Med Chem. 2018 Sep 27;61(18):8078-8087. doi: 10.1021/acs.jmedchem.8b00370.
Michael Siu 1 Arundhati Sengupta Ghosh 1 Joseph W Lewcock 2
Affiliations

Affiliations

  • 1 Genentech, Inc. , 1 DNA Way , South San Francisco , California 94080 , United States.
  • 2 Denali Therapeutics , 151 Oyster Point Boulevard , South San Francisco , California 94080 , United States.
Abstract

Dual leucine zipper kinase (DLK, MAP3K12) is an essential driver of the neuronal stress response that regulates neurodegeneration in models of acute neuronal injury and chronic neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. In this review, we provide an overview of DLK signaling mechanisms and describe selected small molecules that have been utilized to inhibit DLK kinase activity in vivo. These compounds represent valuable tools for understanding the role of DLK signaling and evaluating the potential for DLK inhibition as a therapeutic strategy to prevent neuronal degeneration.

Figures
Products